After agreeing to pay $2.4 billion in Actos settlements to resolve thousands of claims brought by former users of the diabetes drug diagnosed with bladder cancer, Takeda Pharmaceuticals agreed to settle two more claims this week, resolving a two-month trial in Nevada state court.

A tentative agreement was reached to settle an on-going Actos trial involving claims brought by George Decou and the family of Maurice Iorio, who died of bladder cancer in November 2013.

In lawsuits filed in state and federal courts throughout the United States, plaintiffs allege that Takeda knew about the risk of bladder cancer from Actos, but actively withheld the information in an attempt to minimize the impact on sales of their blockbuster treatment.

Prior to reaching the global settlement, Takeda Pharmaceuticals was hit with a groundbreaking $9 billion verdict in the first federal Actos trial, which went before a jury in April 2014. While that verdict was later reduced to $37 million by the U.S. District Judge presiding over the federal litigation, the judge suggested that the evidence presented against Takeda raises questions about whether the U.S. Supreme Court needs to update rules on what is considered excessive in order to effectively deter large corporations from engaging in the type of bad behavior exhibited surrounding Actos.

Decou and Iorio were pursing more than $2 billion in damages at the trial, arguing that Takeda concealed what they knew about Actos risks and “destroyed evidence on a massive scale in an attempt to avoid responsibility.” Details of the settlement have not been disclosed